"The company is in the process of completing its annual planning and expects to provide its full-year 2014 financial outlook in December."
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) flatly denies a press report this morning concerning its long-term forecast, according to which profits from multiple sclerosis treatment Copaxone will drop by 42% in 2014.
"The company is aware of an article published this morning by The Marker in Israel that claims to feature a copy of Teva’s long range financial planning forecast for the years 2013 through 2018. This information, which appears to be from an outdated presentation is incomplete and does not reflect our full analysis, and was provided to The Marker without Teva’s authorization. The company is extremely disappointed that confidential, potentially misleading and obsolete information was made public at this time and intends to investigate the unauthorized dissemination and publication," Teva said in a statement.
The statement goes on to say that "the company is in the process of completing its annual planning and expects to provide its full-year 2014 financial outlook in December and does not intend to comment further until then."
Published by Globes [online], Israel business news - www.globes-online.com - on November 25, 2013
© Copyright of Globes Publisher Itonut (1983) Ltd. 2013